These authors contributed equally.
The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells
Version of Record online: 29 JAN 2013
© 2013 Blackwell Publishing Ltd
British Journal of Haematology
Volume 161, Issue 1, pages 57–67, April 2013
How to Cite
Walsby, E. J., Lazenby, M., Pepper, C. J., Knapper, S. and Burnett, A. K. (2013), The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. British Journal of Haematology, 161: 57–67. doi: 10.1111/bjh.12215
- Issue online: 15 MAR 2013
- Version of Record online: 29 JAN 2013
- Manuscript Accepted: 19 NOV 2012
- Manuscript Received: 7 AUG 2012
|bjh12215-sup-0001-FigS1.tiff||TIFF image||1056K||Fig S1. Responses to NVP-AUY922-AG in primary AML cells in vitro and their distribution with (A) age, (B) sex, (C) FAB group, (D) de novo or secondary AML, E) LD50′s of primary AML cells with FLT3 or NPM1 mutations or combinations of these when treated with NVP-AUY922-AG (F) presenting white blood count. (G) LD50 of AML primary samples and primary non-leukaemia samples to NVP-AUY922-AG.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.